Do analysts recommend ICCC or MRKR?

Marker Therapeutics has a consensus price target of $10.00, indicating a potential upside of 663.36%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Marker Therapeutics is more favorable than ImmuCell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmuCell 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Marker Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Do analysts rate JATT or MRKR?

Marker Therapeutics has a consensus price target of $10.00, indicating a potential upside of 663.36%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Marker Therapeutics is more favorable than JATT Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score JATT Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Marker Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has preferable earnings and valuation, JATT or MRKR?

JATT Acquisition has higher earnings, but lower revenue than Marker Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio JATT Acquisition N/A N/A $6.85M N/A N/A Marker Therapeutics $3.55M 6.15 -$12.16M -$0.61 N/A

Marker Therapeutics (MRKR) Competitors

$1.31 -0.06 (-4.38%)

Closing price 04:00 PM Eastern

Extended Trading

$1.31 0.00 (0.00%)

As of 06:58 PM Eastern

Compare

MRKR vs. TELO, ICCC, CRDF, RNTX, and JATT

Should you buy Marker Therapeutics stock or one of its competitors? MarketBeat compares Marker Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Marker Therapeutics include Telomir Pharmaceuticals (TELO), ImmuCell (ICCC), Cardiff Oncology (CRDF), Rein Therapeutics (RNTX), and JATT Acquisition (JATT). These companies are all part of the "pharmaceutical products" industry.

How does Marker Therapeutics compare to Telomir Pharmaceuticals?

Marker Therapeutics (NASDAQ:MRKR) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, earnings, risk and institutional ownership.

22.4% of Marker Therapeutics shares are held by institutional investors. 5.7% of Marker Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Telomir Pharmaceuticals has lower revenue, but higher earnings than Marker Therapeutics. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics	$3.55M	6.15	-$12.16M	-$0.61	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A

Marker Therapeutics currently has a consensus price target of $10.00, suggesting a potential upside of 663.36%. Given Marker Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Marker Therapeutics is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Telomir Pharmaceuticals has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Marker Therapeutics' return on equity of -73.29% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics	-343.03%	-73.29%	-59.70%
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%

In the previous week, Marker Therapeutics' average media sentiment score of 0.00 equaled Telomir Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Marker Therapeutics	Neutral
Telomir Pharmaceuticals	Neutral

Marker Therapeutics has a beta of 1.44, indicating that its share price is 44% more volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.24, indicating that its share price is 124% less volatile than the broader market.

Summary

Marker Therapeutics beats Telomir Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

How does Marker Therapeutics compare to ImmuCell?

ImmuCell (NASDAQ:ICCC) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership.

ImmuCell has higher revenue and earnings than Marker Therapeutics. ImmuCell is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuCell	$27.64M	3.21	-$1.04M	-$0.06	N/A
Marker Therapeutics	$3.55M	6.15	-$12.16M	-$0.61	N/A

ImmuCell has a net margin of -1.82% compared to Marker Therapeutics' net margin of -343.03%. ImmuCell's return on equity of -1.88% beat Marker Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmuCell	-1.82%	-1.88%	-1.22%
Marker Therapeutics	-343.03%	-73.29%	-59.70%

13.5% of ImmuCell shares are held by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are held by institutional investors. 5.7% of ImmuCell shares are held by company insiders. Comparatively, 5.7% of Marker Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, ImmuCell had 3 more articles in the media than Marker Therapeutics. MarketBeat recorded 3 mentions for ImmuCell and 0 mentions for Marker Therapeutics. ImmuCell's average media sentiment score of 1.14 beat Marker Therapeutics' score of 0.00 indicating that ImmuCell is being referred to more favorably in the media.

Company	Overall Sentiment
ImmuCell	Positive
Marker Therapeutics	Neutral

ImmuCell has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market. Comparatively, Marker Therapeutics has a beta of 1.44, suggesting that its stock price is 44% more volatile than the broader market.

Marker Therapeutics has a consensus price target of $10.00, indicating a potential upside of 663.36%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Marker Therapeutics is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmuCell	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

ImmuCell beats Marker Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Marker Therapeutics compare to Cardiff Oncology?

Cardiff Oncology (NASDAQ:CRDF) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk.

Marker Therapeutics has a net margin of -343.03% compared to Cardiff Oncology's net margin of -8,527.43%. Marker Therapeutics' return on equity of -73.29% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiff Oncology	-8,527.43%	-95.51%	-71.47%
Marker Therapeutics	-343.03%	-73.29%	-59.70%

Marker Therapeutics has higher revenue and earnings than Cardiff Oncology. Marker Therapeutics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiff Oncology	$590K	146.01	-$45.85M	-$0.67	N/A
Marker Therapeutics	$3.55M	6.15	-$12.16M	-$0.61	N/A

Cardiff Oncology presently has a consensus target price of $9.80, indicating a potential upside of 677.78%. Marker Therapeutics has a consensus target price of $10.00, indicating a potential upside of 663.36%. Given Cardiff Oncology's stronger consensus rating and higher probable upside, research analysts plainly believe Cardiff Oncology is more favorable than Marker Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiff Oncology	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Cardiff Oncology had 8 more articles in the media than Marker Therapeutics. MarketBeat recorded 8 mentions for Cardiff Oncology and 0 mentions for Marker Therapeutics. Cardiff Oncology's average media sentiment score of 1.02 beat Marker Therapeutics' score of 0.00 indicating that Cardiff Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Cardiff Oncology	Positive
Marker Therapeutics	Neutral

Cardiff Oncology has a beta of 1.36, meaning that its share price is 36% more volatile than the broader market. Comparatively, Marker Therapeutics has a beta of 1.44, meaning that its share price is 44% more volatile than the broader market.

16.3% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are owned by institutional investors. 8.5% of Cardiff Oncology shares are owned by insiders. Comparatively, 5.7% of Marker Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Cardiff Oncology and Marker Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Marker Therapeutics compare to Rein Therapeutics?

Rein Therapeutics (NASDAQ:RNTX) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment.

90.9% of Rein Therapeutics shares are held by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are held by institutional investors. 1.5% of Rein Therapeutics shares are held by company insiders. Comparatively, 5.7% of Marker Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Rein Therapeutics' average media sentiment score of 1.00 beat Marker Therapeutics' score of 0.00 indicating that Rein Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Rein Therapeutics	Positive
Marker Therapeutics	Neutral

Marker Therapeutics has higher revenue and earnings than Rein Therapeutics. Marker Therapeutics is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.90	N/A
Marker Therapeutics	$3.55M	6.15	-$12.16M	-$0.61	N/A

Rein Therapeutics currently has a consensus price target of $7.00, indicating a potential upside of 593.07%. Marker Therapeutics has a consensus price target of $10.00, indicating a potential upside of 663.36%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Marker Therapeutics is more favorable than Rein Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Rein Therapeutics has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Marker Therapeutics' return on equity of -73.29% beat Rein Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rein Therapeutics	N/A	-510.35%	-68.14%
Marker Therapeutics	-343.03%	-73.29%	-59.70%

Rein Therapeutics has a beta of 1.35, meaning that its stock price is 35% more volatile than the broader market. Comparatively, Marker Therapeutics has a beta of 1.44, meaning that its stock price is 44% more volatile than the broader market.

Summary

Marker Therapeutics beats Rein Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Marker Therapeutics compare to JATT Acquisition?

JATT Acquisition (NYSE:JATT) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.

JATT Acquisition has higher earnings, but lower revenue than Marker Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
JATT Acquisition	N/A	N/A	$6.85M	N/A	N/A
Marker Therapeutics	$3.55M	6.15	-$12.16M	-$0.61	N/A

Marker Therapeutics has a consensus price target of $10.00, indicating a potential upside of 663.36%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Marker Therapeutics is more favorable than JATT Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
JATT Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

48.0% of JATT Acquisition shares are held by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are held by institutional investors. 20.0% of JATT Acquisition shares are held by insiders. Comparatively, 5.7% of Marker Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

JATT Acquisition has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. JATT Acquisition's return on equity of -49.58% beat Marker Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
JATT Acquisition	N/A	-49.58%	2.84%
Marker Therapeutics	-343.03%	-73.29%	-59.70%

In the previous week, JATT Acquisition's average media sentiment score of 0.00 equaled Marker Therapeutics'average media sentiment score.

Company	Overall Sentiment
JATT Acquisition	Neutral
Marker Therapeutics	Neutral

Summary

JATT Acquisition beats Marker Therapeutics on 6 of the 10 factors compared between the two stocks.

Get Marker Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRKR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MRKR vs. The Competition

Export

Metric	Marker Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$21.84M	$3.00B	$6.56B	$12.24B
Dividend Yield	N/A	1.80%	2.69%	5.82%
P/E Ratio	-2.15	18.65	25.17	23.98
Price / Sales	6.15	477.20	553.76	120.62
Price / Cash	N/A	56.31	44.82	54.51
Price / Book	1.30	4.14	10.76	6.41
Net Income	-$12.16M	$64.45M	$3.56B	$337.14M
7 Day Performance	-2.96%	1.34%	1.37%	-0.48%
1 Month Performance	-6.43%	0.95%	0.81%	0.49%
1 Year Performance	-9.03%	24.33%	30.53%	28.16%

Marker Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MRKR Marker Therapeutics	2.5272 of 5 stars	$1.31 -4.4%	$10.00 +663.4%	-3.5%	$21.84M	$3.55M	N/A	60
TELO Telomir Pharmaceuticals	0.4871 of 5 stars	$1.30 +1.6%	N/A	-26.0%	$89.41M	N/A	N/A	1
ICCC ImmuCell	1.5399 of 5 stars	$9.65 -0.9%	N/A	+48.3%	$87.37M	$27.64M	N/A	70	News Coverage Positive News
CRDF Cardiff Oncology	3.2753 of 5 stars	$1.26 -3.1%	$8.75 +594.4%	-60.1%	$86.15M	$590K	N/A	20	News Coverage Analyst Revision
RNTX Rein Therapeutics	4.0845 of 5 stars	$1.00 +10.6%	$7.00 +600.0%	-35.4%	$85.54M	N/A	N/A	9	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MRKR) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Marker Therapeutics (MRKR) Competitors

MRKR vs. TELO, ICCC, CRDF, RNTX, and JATT

How does Marker Therapeutics compare to Telomir Pharmaceuticals?

Summary

How does Marker Therapeutics compare to ImmuCell?

Summary

How does Marker Therapeutics compare to Cardiff Oncology?

Summary

How does Marker Therapeutics compare to Rein Therapeutics?

Summary

How does Marker Therapeutics compare to JATT Acquisition?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRKR vs. The Competition

Marker Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Marker Therapeutics (MRKR) Competitors

MRKR vs. TELO, ICCC, CRDF, RNTX, and JATT

How does Marker Therapeutics compare to Telomir Pharmaceuticals?

Do institutionals and insiders hold more shares of MRKR or TELO?

Which has stronger valuation and earnings, MRKR or TELO?

Do analysts prefer MRKR or TELO?

Is MRKR or TELO more profitable?

Does the media refer more to MRKR or TELO?

Which has more volatility and risk, MRKR or TELO?

Summary

How does Marker Therapeutics compare to ImmuCell?

Which has better valuation & earnings, ICCC or MRKR?

Is ICCC or MRKR more profitable?

Do institutionals & insiders believe in ICCC or MRKR?

Does the media favor ICCC or MRKR?

Which has more risk & volatility, ICCC or MRKR?

Do analysts recommend ICCC or MRKR?

Summary

How does Marker Therapeutics compare to Cardiff Oncology?

Is CRDF or MRKR more profitable?

Which has better valuation and earnings, CRDF or MRKR?

Do analysts prefer CRDF or MRKR?

Does the media favor CRDF or MRKR?

Which has more volatility and risk, CRDF or MRKR?

Do institutionals and insiders believe in CRDF or MRKR?

Summary

How does Marker Therapeutics compare to Rein Therapeutics?

Do institutionals & insiders believe in RNTX or MRKR?

Does the media favor RNTX or MRKR?

Which has higher valuation & earnings, RNTX or MRKR?

Do analysts prefer RNTX or MRKR?

Is RNTX or MRKR more profitable?

Which has more risk & volatility, RNTX or MRKR?

Summary

How does Marker Therapeutics compare to JATT Acquisition?

Which has preferable earnings and valuation, JATT or MRKR?

Do analysts rate JATT or MRKR?

Do insiders & institutionals believe in JATT or MRKR?

Is JATT or MRKR more profitable?

Does the media favor JATT or MRKR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRKR vs. The Competition

Marker Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools